Non-coding RNAs and Hippo signaling in non-small cell lung cancer: emerging roles as biomarkers and therapeutic targets.

IF 2.9 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Discover. Oncology Pub Date : 2025-07-18 DOI:10.1007/s12672-025-03099-6

Mohammadamin Joulani, Nahal Aghajamal, Masoumeh Nouri, Faraz Rahmani Khajeh, Nafiseh Sharifi, Dena Saghafi, Mahan Amiri, Ali Abdollahzadeh, Ehsan Heidari, Amin Mirdamadian, Malihe Sharafi, Samira Masoumi, Reza Morovatshoar, Alireza Azani, Qumars Behfar

{"title":"Non-coding RNAs and Hippo signaling in non-small cell lung cancer: emerging roles as biomarkers and therapeutic targets.","authors":"Mohammadamin Joulani, Nahal Aghajamal, Masoumeh Nouri, Faraz Rahmani Khajeh, Nafiseh Sharifi, Dena Saghafi, Mahan Amiri, Ali Abdollahzadeh, Ehsan Heidari, Amin Mirdamadian, Malihe Sharafi, Samira Masoumi, Reza Morovatshoar, Alireza Azani, Qumars Behfar","doi":"10.1007/s12672-025-03099-6","DOIUrl":null,"url":null,"abstract":"<p><p>The most common type of cancer and one with a high death rate is lung cancer, especially non-small cell lung cancer (NSCLC), which is mostly brought on by medication resistance, metastasis, and delayed diagnosis. The discovery of non-coding RNAs (ncRNAs), such as circular RNAs (circRNAs), long non-coding RNAs (lncRNAs), and microRNAs (miRNAs), has revealed their vital involvement in the pathophysiology of lung cancer by controlling important cellular processes. The Hippo signaling pathway is one of the critical routes impacted by non-coding RNAs. It is involved in tumor suppression, apoptosis, and cell proliferation. The interaction between ncRNAs and the Hippo pathway in lung cancer is reviewed in this review, with an emphasis on the potential of these molecules as therapeutic targets as well as diagnostic and prognostic biomarkers.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1365"},"PeriodicalIF":2.9000,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12274179/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discover. Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-025-03099-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

The most common type of cancer and one with a high death rate is lung cancer, especially non-small cell lung cancer (NSCLC), which is mostly brought on by medication resistance, metastasis, and delayed diagnosis. The discovery of non-coding RNAs (ncRNAs), such as circular RNAs (circRNAs), long non-coding RNAs (lncRNAs), and microRNAs (miRNAs), has revealed their vital involvement in the pathophysiology of lung cancer by controlling important cellular processes. The Hippo signaling pathway is one of the critical routes impacted by non-coding RNAs. It is involved in tumor suppression, apoptosis, and cell proliferation. The interaction between ncRNAs and the Hippo pathway in lung cancer is reviewed in this review, with an emphasis on the potential of these molecules as therapeutic targets as well as diagnostic and prognostic biomarkers.

查看原文本刊更多论文

非编码rna和Hippo信号在非小细胞肺癌中的作用：作为生物标志物和治疗靶点的新角色。

肺癌是最常见的癌症，也是死亡率最高的癌症之一，尤其是非小细胞肺癌（NSCLC），它主要是由耐药、转移和延迟诊断引起的。非编码rna （ncRNAs）的发现，如环状rna （circRNAs）、长链非编码rna （lncRNAs）和微rna (miRNAs)，揭示了它们通过控制重要的细胞过程参与肺癌的病理生理。Hippo信号通路是受非编码rna影响的关键通路之一。它参与肿瘤抑制、细胞凋亡和细胞增殖。本文综述了肺癌中ncRNAs与Hippo通路之间的相互作用，重点介绍了这些分子作为治疗靶点以及诊断和预后生物标志物的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊